[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Moroishi et al., 2016 - Google Patents

The Hippo pathway kinases LATS1/2 suppress cancer immunity

Moroishi et al., 2016

View HTML @Full View
Document ID
4866946901515427467
Author
Moroishi T
Hayashi T
Pan W
Fujita Y
Holt M
Qin J
Carson D
Guan K
Publication year
Publication venue
Cell

External Links

Snippet

Poorly immunogenic tumor cells evade host immunity and grow even in the presence of an intact immune system, but the complex mechanisms regulating tumor immunogenicity have not been elucidated. Here, we discovered an unexpected role of the Hippo pathway in …
Continue reading at www.cell.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Moroishi et al. The Hippo pathway kinases LATS1/2 suppress cancer immunity
US11597934B2 (en) Methods and compositions for reducing immunosuppression by tumor cells
Woo et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors
McDaniel et al. Suppression of inflammasome activation by IRF8 and IRF4 in cDCs is critical for T cell priming
US11865176B2 (en) Compositions and methods of modulating anti-tumor immunity
Hargadon Strategies to improve the efficacy of dendritic cell-based immunotherapy for melanoma
Urabe et al. Extracellular vesicles: toward a clinical application in urological cancer treatment
Flosbach et al. PTPN2 deficiency enhances programmed T cell expansion and survival capacity of activated T cells
Tsuchiya et al. Type I interferon delivery by iPSC-derived myeloid cells elicits antitumor immunity via XCR1+ dendritic cells
Khalife et al. Extracellular vesicles in hematological malignancies: from biomarkers to therapeutic tools
Jeyanathan et al. Pulmonary M. tuberculosis infection delays Th1 immunity via immunoadaptor DAP12-regulated IRAK-M and IL-10 expression in antigen-presenting cells
Fearon Immune-suppressing cellular elements of the tumor microenvironment
WO2018085275A1 (en) Targeting lats1/2 and the hippo intracellular signaling pathway for cancer immunotherapy
Abusarah et al. Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice
Deng et al. Tumor cell senescence-induced macrophage CD73 expression is a critical metabolic immune checkpoint in the aging tumor microenvironment
US20200087625A1 (en) Methods for isolating, expanding and administering cancer specific cd8+ t cells
Heidegger et al. Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapy
Mender et al. Activating an adaptive immune response with a telomerase-mediated telomere targeting therapeutic in hepatocellular carcinoma
US9795660B2 (en) Id-protein targeted tumor cell vaccine
Tang et al. miR-aculous new avenues for cancer immunotherapy
CN108697762A (en) The composition and method for the treatment of cancer
JP2015517655A (en) Compositions and methods for treating B-lymphoid malignancy
Biswas CCL2 Suppression in Lewis Lung Carcinoma Model Enhances Host Survival and Immune Response in the Tumor Microenvironment
Chaib Targeting Myeloid Protein Kinase C Signaling to Overcome Immune Suppression and Improve Immunotherapy in Cancer
Kanikarla Marie et al. Preeti Kanikarla Marie1†, Alexey V. Sorokin1†, Lea A. Bitner1, Rebecca Aden1, Michael Lam1, Ganiraju Manyam2, Melanie N. Woods1, Amanda Anderson1, Anna Capasso3, Natalie Fowlkes 4, Michael J. Overman1, David G. Menter1 and Scott Kopetz1